Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medicine should be based on the patient’s current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use 2. Patients who must not receive this medicine).
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients who must not receive this medicine).
Improvement of glycemic control in type 2 diabetes mellitus
Difficulty in blood sugar control in patients with type 2 diabetes
View approved original textHide original text
This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It is helpful when initial monotherapy is insufficient to control blood sugar in newly treated diabetes patients. This medication can also be substituted or used in combination when metformin or sitagliptin monotherapy is inadequate. It may be combined when combinations such as metformin with sulfonylureas or metformin with thiazolidinediones are ineffective. Additionally, for patients who find it difficult to control blood sugar while on insulin and metformin, this medication can be added to enhance therapeutic efficacy. It is used in the previously mentioned scenarios to improve blood sugar control.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medicine should be based on the patient’s current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use 2. Patients who must not receive this medicine).
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients who must not receive this medicine).
Precautions
This medication contains sitagliptin and metformin, and is used in diabetes treatment.
First, during the administration of this medication, severe allergic reactions may occur, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck arise, you should stop taking the medication immediately and inform a healthcare professional.
Furthermore, there is a risk of developing acute pancreatitis, a serious inflammation of the pancreas, so symptoms such as abdominal pain, nausea, vomiting, and fever should be closely monitored, and if suspected, consult a doctor immediately.
Metformin, one of the ingredients in this medication, can rarely provoke a serious metabolic disorder called lactic acidosis, which may manifest as muscle pain, difficulty breathing, weakness, and abdominal pain. If these symptoms appear, you must stop taking the medication immediately and seek emergency treatment.
Patients with severely impaired kidney function, acute cardiac failure, severe infection, or dehydration should not take this medication and should discontinue it before and after examinations using contrast media containing iodine.
It is safer not to use this medication in pregnant women or women who may become pregnant, or in nursing mothers.
During the course of treatment, symptoms of hypoglycemia may occur, so especially when taken with other hypoglycemic agents or insulin, blood sugar levels should be monitored frequently and attention should be paid to symptoms of hypoglycemia.
Additionally, there is an increased risk of hypoglycemia during intense exercise, irregular meals, or poor nutritional status, so caution is needed.
Regular monitoring of liver and kidney function during treatment is necessary to ensure there are no abnormalities, and since vitamin B12 deficiency may occur, it is advisable to periodically check vitamin levels.
Alcohol consumption may increase risks when taken with this medication, so it is preferable to avoid alcohol.
During states where oral ingestion is difficult due to surgery, severe infection, or significant trauma, temporarily discontinuing this medication and restarting it after recovery is necessary.
Finally, joint pain, skin rash, or blistering skin diseases may develop during treatment, so if such symptoms appear, consult a physician.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory infection
headache
nausea
Show 22 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe and disabling arthralgia
vesicular pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
dermatitis
anorexia
weight loss
dyspnea
unstable angina
dizziness
acute renal failure
decreased appetite
gastrointestinal disorders
itching
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly closed container to prevent air exposure, and it is best kept at room temperature between 1 to 30 degrees Celsius. Proper storage conditions help maintain the medication's effectiveness.
Appearance and packaging
Appearance
Pink oval film-coated tablet
Package unit
30 tablets/box [(10 tablets/PTP x 3)]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.